(NC5505) Molecular Strategy to Meningioma

Monday, April 24, 2023

9:16am – 9:32am PST

Location: Los Angeles Convention Center, 411- Theater

Speaker(s)

Jennifer Moliterno Gunel, MD

Chief, Neurosurgical Oncology
Department of Neurosurgery, Yale School of Medicine
New Haven, Connecticut, United States

Moderator(s)

Chetan Bettegowda, MD, PhD (he/him/his)

Professor and Vice Chair
Johns Hopkins
Baltimore, Maryland, United States
Gordon Li, MD

Professor and Vice Chair, Faculty Affairs
Stanford University Department of Neurosurgery
Stanford, California, United States

Disclosure(s):

Jennifer Moliterno Gunel, MD: BK Medical: Consultant (Ongoing)

Chetan Bettegowda, MD, PhD: Belay Diagnostics: Board Member/Officer/Trustee (Ongoing), Ownership Interest (Ongoing); Bionaut Labs: Consultant (Ongoing); Depuy-Synthes: Consultant (Ongoing); Galectin Therapeutics: Consultant (Ongoing); Haystack Oncology: Consultant (Ongoing); OrisDx: Board Member/Officer/Trustee (Ongoing), Ownership Interest (Ongoing); Privo Technology: Consultant (Ongoing)

Gordon Li, MD: Abbott: Stock Shareholder (excluding mutual funds) (Ongoing); Biogen: Stock Shareholder (excluding mutual funds) (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); Bristol Myers Squibb: Grant/Research Support (Terminated, February 6, 2023); gilead: Stock Shareholder (excluding mutual funds) (Ongoing); J&J/Synthes: Speaker/Honoraria (Terminated, February 6, 2023); Medtronic: Consultant (Ongoing); Merck: Stock Shareholder (excluding mutual funds) (Ongoing); Novocure: Grant/Research Support (Ongoing); Pfizer: Stock Shareholder (excluding mutual funds) (Ongoing); Photonic Medical: Advisor (Ongoing), Consultant (Ongoing), Ownership Interest (Ongoing); stryker: Stock Shareholder (excluding mutual funds) (Ongoing)